Hormonal
Impaired postprandial lipid metabolism, characterized by higher triglyceride and free fatty acid responses to an oral fat load, is linked to hypoadiponectinemia and independently predicts the severity of hepatic steatosis in NASH patients.
For NASH patients, the type and amount of fat consumed in a single meal can significantly impact liver fat accumulation. Since postprandial free fatty acids independently predict steatosis severity, managing post-meal lipid spikes through dietary fat quality (higher PUFA, lower SFA) is a practical strategy to support liver health.
The magnitude of postprandial lipemia was significantly higher in NASH than in controls and was related to fasting adiponectin... Postprandial free fatty acids response correlated inversely with adiponectin response in both groups and independently predicted the severity of liver steatosis in NASH
Why this rating
The use of an oral fat load test provides dynamic, functional data on lipid metabolism, strengthening the cross-sectional findings.
Source
Adipokines in NASH: Postprandial Lipid Metabolism as a Link Between Adiponectin and Liver Disease *
Giovanni Musso et al. · Hepatology · 2005
DOI 10.1002/hep.20896
More from this paper
- Low circulating adiponectin levels are independently associated with the severity of liver histology (steatosis, necroinflammation, and fibrosis) in non-obese, non-diabetic patients with NASH, and this hypoadiponectinemia predicts impaired postprandial lipid metabolism.Good
- Dietary intake of polyunsaturated fatty acids (PUFA) is positively associated with fasting adiponectin levels, while saturated fatty acid (SFA) intake is negatively associated, suggesting that dietary fat quality modulates adiponectin secretion.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →